Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Payables: 2017-2024

Historic Payables for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $18.0 million.

  • Arcus Biosciences' Payables rose 223.08% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.0 million, marking a year-over-year increase of 81.97%. This contributed to the annual value of $18.0 million for FY2024, which is 5.88% up from last year.
  • Latest data reveals that Arcus Biosciences reported Payables of $18.0 million as of FY2024, which was up 5.88% from $17.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Payables registered a high of $20.0 million during FY2022, and its lowest value of $10.0 million during FY2021.
  • For the 3-year period, Arcus Biosciences' Payables averaged around $18.3 million, with its median value being $18.0 million (2024).
  • In the last 5 years, Arcus Biosciences' Payables skyrocketed by 233.38% in 2020 and then crashed by 36.23% in 2021.
  • Arcus Biosciences' Payables (Yearly) stood at $15.7 million in 2020, then tumbled by 36.23% to $10.0 million in 2021, then surged by 100.00% to $20.0 million in 2022, then declined by 15.00% to $17.0 million in 2023, then increased by 5.88% to $18.0 million in 2024.